Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma

BACKGROUND: Sorafenib is the first-line treatment for advanced-stage hepatocellular carcinoma (HCC). Several studies have shown that the up-regulation of β-catenin plays a role in sorafenib resistance in HCC; however, the mechanism associated with this phenomenon remains elusive. METHODS: Western bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Ling, Sun, Jingyuan, Chen, Xiaohui, Liu, Li, Wu, Dehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639974/
https://www.ncbi.nlm.nih.gov/pubmed/31319849
http://dx.doi.org/10.1186/s13046-019-1311-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639974/
https://www.ncbi.nlm.nih.gov/pubmed/31319849
http://dx.doi.org/10.1186/s13046-019-1311-z

Ejemplares similares